Tiny study probes why antibiotic may tame rare vasculitis
NCT ID NCT03919435
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how the antibiotic TMP-SMX changes the bacteria and fungi living in the noses of people with granulomatosis with polyangiitis (GPA), a rare autoimmune disease. Researchers want to understand why this antibiotic helps prevent disease flare-ups. Eight adults with GPA and a history of sinus problems will take TMP-SMX for 4 weeks, and their nasal microbiome will be tracked over 6 months using swabs and optional blood draws.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trimethoprim-sulfamethoxazole (TMP-SMX), an antibiotic pill
- What this could lead to
- If successful, this study could reveal whether TMP-SMX prevents GPA relapses by killing bacteria or by reducing inflammation, guiding better treatments.
- What could go wrong
- This is a very small, early-phase study with only 8 participants, so results may not apply to all GPA patients. It is designed to observe changes, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Promising vasculitis drug trial halted early
- Experimental liquid drug tested in ventilator patients with rare lung bleeding disease
- Hydroxychloroquine trial for rare vasculitis halted early
- New hope for Wegener's patients: drug aims to stop flare-ups
- New hope for rare vasculitis: Three-Drug trial targets Non-Responders
- Steroid showdown: can a tiny daily dose keep a rare disease at bay?